Full history for every metric is available with a Kvantra account
Dna Group (T.R.) Ltd (DNA.TA)
Key financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ILS m | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Operating profit | ILS m | 21 | - | |||||
| Net profit | ILS m | -39 | -19 | 18 | -24 | -1 | 22 | - |
| EPS reported | ILS | 0.18 | - | |||||
| Operating cashflow per share | ILS | 0.01 | 0.01 | |||||
| Capex per share | ILS | 0.00 | 0.00 | |||||
| FCF per share | ILS | 0.01 | 0.01 | |||||
| Free cash flow | ILS m | 2 | 2 | |||||
| Net debt | ILS m | -68 | -70 | |||||
| Book value equity | ILS m | 101 | 98 | |||||
| Book value per share | ILS | 0.82 | 0.80 | |||||
| Number of shares | m | 123.19 | 123.16 | |||||
| DPS (TTM paid) | ILS | 0.00 | 0.00 |
Financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 4.86 | - | |||||
| P/B LTM | x | 1.06 | 1.39 | |||||
| P/S LTM | x | 351.87 | 446.36 | |||||
| P/FCF LTM | x | 66.88 | 67.09 | |||||
| EV/EBITDA LTM | x | -26.07 | 0.00 | |||||
| EV/Sales LTM | x | 128.63 | 216.54 | |||||
| Earnings Yield LTM | % | 20.58% | -2.07% | |||||
| FCF Yield | % | 1.50% | 1.49% | |||||
| Quality | ||||||||
| ROE | % | 21.78% | -2.85% | |||||
| ROIC | % | 18.87% | -2.78% | |||||
| Operating margin | % | 6736.6% | -1966.0% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | 526.14% | 560.78% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | 0.00% | 0.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | +616.90% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 45.24 | 0.00 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -63.44% | -51.49% | |||||
| Net debt/Equity | x | -0.67 | -0.72 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Dna Group (T.R.) Ltd, along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of proprietary ultrasound technologies. These advanced systems are utilized to evaluate bone strength and density, as well as to detect and monitor calcium leakage associated with osteoporosis in both adult and pediatric patients. The company's offerings are employed by trained physicians, nurses, and operators within hospitals, clinics, pharmacies, and various other healthcare environments across Israel, North America, East Asia, and international markets. Beyond its core ultrasound business, the group is also involved in the creation of oral medications. Established in 2004 and based in Tel Aviv-Yafo, Israel, the company was formerly known as D.N.A Biomedical Solutions Ltd. before adopting its current name in November 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dna Group (T.R.) Ltd (DNA.TA)
Dna Group (T.R.) Ltd, along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of proprietary ultrasound technologies. These advanced systems are utilized to evaluate bone strength and density, as well as to detect and monitor calcium leakage associated with osteoporosis in both adult and pediatric patients. The company's offerings are employed by trained physicians, nurses, and operators within hospitals, clinics, pharmacies, and various other healthcare environments across Israel, North America, East Asia, and international markets. Beyond its core ultrasound business, the group is also involved in the creation of oral medications. Established in 2004 and based in Tel Aviv-Yafo, Israel, the company was formerly known as D.N.A Biomedical Solutions Ltd. before adopting its current name in November 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free